BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008;47:1371-83. [PMID: 18240152 DOI: 10.1002/hep.22127] [Cited by in Crossref: 196] [Cited by in F6Publishing: 184] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Buti M, Calleja JL, Lens S, Diago M, Ortega E, Crespo J, Planas R, Romero-Gómez M, Rodríguez FG, Pascasio JM, Fevery B, Kurland D, Corbett C, Kalmeijer R, Jessner W. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther 2017;45:468-75. [PMID: 27896822 DOI: 10.1111/apt.13883] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
2 El-karaksy HM, Sharaf SA, Mandour IA, Mogahed EA, Rady NH, El- Mougy FA. Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection. Human Immunology 2016;77:1248-53. [DOI: 10.1016/j.humimm.2016.09.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Li Y, Wang R, Du X, Zhang M, Xie M. Genome-wide analysis for identification of adaptive diversification between hepatitis C virus subtypes 1a and 1b. Can J Microbiol 2016;62:608-16. [PMID: 27277863 DOI: 10.1139/cjm-2016-0156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Helal GK, Gad MA, Abd-Ellah MF, Eid MS. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol 2016;88:2170-8. [PMID: 27183377 DOI: 10.1002/jmv.24575] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
5 Maieron A, Metz-Gercek S, Hackl F, Ziachehabi A, Fuchsteiner H, Luger C, Mittermayer H, Schöfl R. Antiviral treatment of chronic hepatitis C in clinical routine. Wien Klin Wochenschr. 2010;122:237-242. [PMID: 20503023 DOI: 10.1007/s00508-010-1364-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
6 Jackowiak P, Kuls K, Budzko L, Mania A, Figlerowicz M, Figlerowicz M. Phylogeny and molecular evolution of the hepatitis C virus. Infect Genet Evol. 2014;21:67-82. [PMID: 24200590 DOI: 10.1016/j.meegid.2013.10.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
7 De Meyer S, Ghys A, Dierynck I, Beumont M, Luo D, Picchio G. Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virol J. 2014;11:93. [PMID: 24886541 DOI: 10.1186/1743-422x-11-93] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ghobrial C, Sobhy R, Mogahed E, Abdullatif H, El-Karaksy H. Is sofosbuvir/ledipasvir safe for the hearts of children with hepatitis C virus? Dig Liver Dis 2019;51:258-62. [PMID: 30316789 DOI: 10.1016/j.dld.2018.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
9 Zayed RA, Rushdy E, Saleh DA. Detection of HCV RNA in the Peripheral Blood Mononuclear Cells of Serum HCV RNA-Negative Egyptian Patients Under Interferon Treatment. The American Journal of the Medical Sciences 2010;340:435-8. [DOI: 10.1097/maj.0b013e3181ec435e] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
10 Bolcic F, Jones L, Laufer N, Quarleri J. Molecular characterization of hepatitis C virus genotype 4 sequences in HIV-coinfected patients from Argentina. J Med Virol 2011;83:935-40. [DOI: 10.1002/jmv.22068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
11 Boyd SD, Harrington P, Komatsu TE, Naeger LK, Chan-tack K, Murray J, Birnkrant D, Struble K. HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens. J Viral Hepat 2018;25:969-75. [DOI: 10.1111/jvh.12896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Nouroz F, Shaheen S, Mujtaba G, Noreen S. An overview on hepatitis C virus genotypes and its control. Egyptian Journal of Medical Human Genetics 2015;16:291-8. [DOI: 10.1016/j.ejmhg.2015.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
13 Shehab H, Elbaz T, Deraz D, Hafez A, Elattar I. The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C. J Interferon Cytokine Res 2014;34:727-33. [PMID: 24730368 DOI: 10.1089/jir.2013.0127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
14 Mwangi J, Nganga Z, Mpoke S, Lihana R, Kinyua J, Lagat N, Muriuki J, Lel R, Kageha S, Osman S, Ichimura H. Hepatitis C virus genotypes in Kenya. Arch Virol 2016;161:95-101. [PMID: 26497178 DOI: 10.1007/s00705-015-2623-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
15 Yang S, Kao J. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 2014;9:9-20. [DOI: 10.1586/17474124.2014.953930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
16 Ntagirabiri R, Poveda JD, Mumana A, Ndayishimiye H. Genotypes and subtypes of hepatitis C virus in Burundi: a particularity in sub-Saharan Africa. Pan Afr Med J 2014;19:69. [PMID: 25709727 DOI: 10.11604/pamj.2014.19.69.4580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Shehab HM, Elbaz TM, Deraz DM. Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial. Liver Int 2014;34:259-65. [DOI: 10.1111/liv.12267] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
18 Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Dekhtyar T, Irvin M, Hall C, Yu Y, Mobashery N, Redman R, Pilot-Matias T, Collins C. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir. J Viral Hepat 2018;25:1078-88. [PMID: 29624809 DOI: 10.1111/jvh.12906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Abdo AA, Sanai FM. Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects. Ann Saudi Med 2009;29:1-3. [PMID: 19139625 DOI: 10.4103/0256-4947.51810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
20 Lashin AH, Shaheen YA, Metwally MA, El-Feky HM, Hegab MF, Abbas SM. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin. Indian J Gastroenterol 2013;32:316-23. [PMID: 23715642 DOI: 10.1007/s12664-013-0336-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
21 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
22 Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, Esteban R, Abdo AA, Harrison SA, Ibrahim N, Cacoub P, Eslam M, Lee SS. Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel. Journal of Hepatology 2011;54:1250-62. [DOI: 10.1016/j.jhep.2010.11.016] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 7.8] [Reference Citation Analysis]
23 Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010;14:1-21, vii. [PMID: 20123436 DOI: 10.1016/j.cld.2009.11.009] [Cited by in Crossref: 276] [Cited by in F6Publishing: 239] [Article Influence: 23.0] [Reference Citation Analysis]
24 Yahia M. Global health: a uniquely Egyptian epidemic. Nature. 2011;474:S12-S13. [PMID: 21666728 DOI: 10.1038/474s12a] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
25 Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
26 Elsadek Fakhr A, Pourkarim MR, Maes P, Atta AH, Marei A, Azab M, Van Ranst M. Hepatitis C Virus NS5B Sequence-Based Genotyping Analysis of Patients From the Sharkia Governorate, Egypt. Hepat Mon 2013;13:e12706. [PMID: 24358038 DOI: 10.5812/hepatmon.12706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
27 El-karaksy HM, Mogahed EA, El-raziky MS, Saleh D, Besheer M, Mubarak S. Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children. Journal of Interferon & Cytokine Research 2016;36:1-8. [DOI: 10.1089/jir.2015.0066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
28 Abu Faddan NH, Shehata GA, Abd Elhafeez HA, Mohamed AO, Hassan HS, Abd El Sameea F. Cognitive function and endogenous cytokine levels in children with chronic hepatitis C. J Viral Hepat. 2015;22:665-670. [PMID: 25496114 DOI: 10.1111/jvh.12373] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
29 Darling JM, Fried MW. Nitazoxanide: Beyond Parasites Toward a Novel Agent for Hepatitis C. Gastroenterology 2009;136:760-3. [DOI: 10.1053/j.gastro.2009.01.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
30 El-Guendy NM, Helwa R, El-Halawany MS, Abdel Rahman Ali S, Tantawy Aly M, Hasan Alieldin N, Fouad SA, Saeid H, Abdel-Wahab AH. The Liver MicroRNA Expression Profiles Associated With Chronic Hepatitis C Virus (HCV) Genotype-4 Infection: A Preliminary Study. Hepat Mon 2016;16:e33881. [PMID: 27275163 DOI: 10.5812/hepatmon.33881] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
31 El-Dahshan D, Bahy D, Wahid A, Ahmed AE, Hanora A. Two novel SNPs in the promoter region of PKR gene in hepatitis C patients and their impact on disease outcome and response to treatment. Arab J Gastroenterol 2018;19:106-15. [PMID: 30245117 DOI: 10.1016/j.ajg.2018.06.002] [Reference Citation Analysis]
32 Prakash S, Shukla S, Ramakrishna V, Jain A. Distribution of hepatitis C genotypes in Uttar Pradesh, India; rare genotype 4 detected. J Med Virol 2018;90:1875-81. [PMID: 30085356 DOI: 10.1002/jmv.25277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
33 Fathy MM, Abo Taleb ME, El Hawary MS, Nabih MI, Aref WM, Makhlouf MM. Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients. Cytokine 2015;74:268-72. [PMID: 26003758 DOI: 10.1016/j.cyto.2015.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
34 Assem M, Yousri M. Impact of pentoxifylline and vitamin e on ribavirin-induced haemolytic anaemia in chronic hepatitis C patients: an egyptian survey. Int J Hepatol 2011;2011:530949. [PMID: 21994862 DOI: 10.4061/2011/530949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
35 Ayesh BM, Zourob SS, Abu-Jadallah SY, Shemer-Avni Y. Most common genotypes and risk factors for HCV in Gaza strip: a cross sectional study. Virol J. 2009;6:105. [PMID: 19607718 DOI: 10.1186/1743-422x-6-105] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
36 Saleh O, Baiomy AA, El-desouky A, Zaghloul H, El-Arman M, Dahab GM, Abdel-Rahman MS. Hepatitis C virus genotype distribution in Egyptian diabetic patients: a preliminary study. Arab J Gastroenterol 2013;14:14-9. [PMID: 23622804 DOI: 10.1016/j.ajg.2013.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Elefsiniotis IS, Pavlidis C, Dimitroulopoulos D, Vezali E, Mihas C, Mariolis-Sapsakos T, Koutsounas S, Paraskevas E, Saroglou G. Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity. J Viral Hepat. 2009;16:738-742. [PMID: 19413697 DOI: 10.1111/j.1365-2893.2009.01134.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
38 Aygen B, Yıldız O, Akhan S, Çelen MK, Ural O, Koruk ST, Köse Ş, Korkmaz F, Kuruüzüm Z, Tuna N, Taheri S, Sayan M, Demir NA, Sümer Ş, Altınok ES. Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. Balkan Med J 2015;32:266-72. [PMID: 26185714 DOI: 10.5152/balkanmedj.2015.15366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
39 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562. [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107] [Cited by in Crossref: 692] [Cited by in F6Publishing: 617] [Article Influence: 76.9] [Reference Citation Analysis]
40 Aytaman A, Kaufman M, Terrault NA. Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant. 2010;15:301-309. [PMID: 20445452 DOI: 10.1097/mot.0b013e3283398237] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Sarin SK, Kumar M. Natural history of HCV infection. Hepatol Int 2012;6:684-95. [DOI: 10.1007/s12072-012-9355-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
42 Shibl A, Senok A, Memish Z. Infectious diseases in the Arabian Peninsula and Egypt. Clin Microbiol Infect 2012;18:1068-80. [PMID: 23066725 DOI: 10.1111/1469-0691.12010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
43 Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P, Gaeta GB, Leonardi C, Levrero M, Mazzotta F, Morrone A, Nosotti L, Prati D, Rapicetta M, Sagnelli E, Scotto G, Starnini G. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Digestive and Liver Disease 2011;43:589-95. [DOI: 10.1016/j.dld.2010.12.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
44 Abdallah F, Mohamed G, Ibrahim M, El Tarabily M. Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4. Am J Med Sci 2018;355:456-66. [PMID: 29753376 DOI: 10.1016/j.amjms.2017.12.016] [Reference Citation Analysis]
45 El-Mahallawy HA, Mohsen LM, Wassef M. Milestones along the road of infection prevention in Egypt. Eur J Clin Microbiol Infect Dis 2015;34:1923-8. [PMID: 26231169 DOI: 10.1007/s10096-015-2444-4] [Reference Citation Analysis]
46 Hundie GB, Raj VS, GebreMichael D, Pas SD, Haagmans BL. Genetic diversity of hepatitis C virus in Ethiopia. PLoS One 2017;12:e0179064. [PMID: 28570623 DOI: 10.1371/journal.pone.0179064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
47 Fourati S, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L, Chevaliez S, Pawlotsky JM. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. Hepatology 2019;69:513-23. [PMID: 30125371 DOI: 10.1002/hep.30225] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 21.3] [Reference Citation Analysis]
48 Abbas OM, Abdel-Rahman MH, Omar NA, Badran HM, Amir EM. Interleukin-10 promoter polymorphisms in hepatitis C patients with and without Schistosoma mansoni co-infection. Liver Int 2009;29:1422-30. [PMID: 19555400 DOI: 10.1111/j.1478-3231.2009.02068.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
49 Jang JY, Chung RT. Chronic hepatitis C. Gut Liver. 2011;5:117-132. [PMID: 21814590 DOI: 10.5009/gnl.2011.5.2.117] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
50 Seremba E, Ocama P, Opio CK, Kagimu M, Thomas DL, Yuan HJ, Attar N, Lee WM. Poor performance of hepatitis C antibody tests in hospital patients in Uganda. J Med Virol 2010;82:1371-8. [PMID: 20572078 DOI: 10.1002/jmv.21817] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
51 Demetriou VL, Kostrikis LG. Molecular epidemiology of hepatitis C infection in Cyprus within the general population and high-risk cohorts. BMC Res Notes 2011;4:468. [PMID: 22040780 DOI: 10.1186/1756-0500-4-468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
52 Helal GK, Gad MA, Abd-Ellah MF, Mahgoup EM. Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients. Eur J Gastroenterol Hepatol 2016;28:553-7. [PMID: 26872109 DOI: 10.1097/MEG.0000000000000587] [Reference Citation Analysis]
53 Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 – the new treatment challenge. Aliment Pharmacol Ther. 2014;39:686-698. [PMID: 24612116 DOI: 10.1111/apt.12646] [Cited by in Crossref: 87] [Cited by in F6Publishing: 85] [Article Influence: 10.9] [Reference Citation Analysis]
54 Conde I, Vinaixa C, Berenguer M. Hepatitis C-related cirrhosis. Current status. Med Clin (Barc) 2017;148:78-85. [PMID: 27855947 DOI: 10.1016/j.medcli.2016.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Montoya-Ferrer A, Fierer DS, Alvarez-Alvarez B, de Gorgolas M, Fernandez-Guerrero ML. Acute hepatitis C outbreak among HIV-infected men, Madrid, Spain. Emerg Infect Dis 2011;17:1560-2. [PMID: 21801652 DOI: 10.3201/eid1708.110147] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
56 Wahsh EA, Hussein AK, Gomaa AA, Baraka MA, Al-Deen Abead M. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients. Infect Disord Drug Targets 2020;20:43-8. [PMID: 30009715 DOI: 10.2174/1871526518666180716141806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Megahed A, Salem N, Fathy A, Barakat T, Alsayed MAEL, Mabood SAE, Zalata KR, Abdalla AF. Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection. World J Pediatr 2017;13:346-52. [DOI: 10.1007/s12519-017-0013-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
58 Kamal SM, Mahmoud S, Hafez T, El-Fouly R. Viral hepatitis a to e in South mediterranean countries. Mediterr J Hematol Infect Dis 2010;2:e2010001. [PMID: 21415943 DOI: 10.4084/MJHID.2010.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
59 Kchouk FH, Gorgi Y, Bouslama L, Sfar I, Ayari R, Khiri H, Halfon P, Aouadi H, Jendoubi Ayed S, Ayed K. Phylogenetic analysis of isolated HCV strains from tunisian hemodialysis patients. Viral Immunol. 2013;26:40-48. [PMID: 23374151 DOI: 10.1089/vim.2012.0043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
60 Kohla MA, El-Said H, El-Fert A, Ehsan N, Ezzat S, Taha H. Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: a double-blind placebo-controlled trial. Eur J Gastroenterol Hepatol 2016;28:42-7. [PMID: 26473300 DOI: 10.1097/MEG.0000000000000492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 El-Fatah Fahmy Hanno A, Mohiedeen KM, Deghedy A, Sayed R. Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment. Arab J Gastroenterol 2014;15:58-62. [PMID: 25097047 DOI: 10.1016/j.ajg.2014.04.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
62 Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int. 2014;34:890-895. [PMID: 24102823 DOI: 10.1111/liv.12321] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
63 Eriksen MB, Jørgensen LB, Krarup H, Laursen AL, Christensen PB, Møller A, Schlichting P, Kuiken C, Bukh J, Weis N; DANHEP Group. Molecular and epidemiological profiles of hepatitis C virus genotype 4 in Denmark. J Med Virol 2010;82:1869-77. [PMID: 20872713 DOI: 10.1002/jmv.21896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
64 Kamal SM, Kassim S, El Gohary E, Fouad A, Nabegh L, Hafez T, Bahnasy K, Hassan H, Ghoraba D. The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2015;42:307-18. [PMID: 26018116 DOI: 10.1111/apt.13261] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
65 Mohamed WA, Schaalan MF, El-Abhar HS. Camel Milk: Potential Utility as an Adjunctive Therapy to Peg-IFN/RBV in HCV-4 Infected Patients in Egypt. Nutr Cancer 2015;67:1305-13. [PMID: 26492130 DOI: 10.1080/01635581.2015.1087041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
66 Zayed RA, Omran D, Zayed AA, Elmessery LO. Determinants of Infection Outcome in HCV-Genotype 4. Viral Immunol. 2017;30:560-567. [PMID: 28731371 DOI: 10.1089/vim.2017.0071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
67 Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG. Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. AIDS Res Hum Retroviruses 2016;32:660-7. [PMID: 26974581 DOI: 10.1089/aid.2015.0236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
68 Sereno S, Perinelli P, Laghi V. Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol. 2009;45:354-357. [PMID: 19497783 DOI: 10.1016/j.jcv.2009.04.022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
69 Salehi Moghadam F, Mohebbi SR, Hosseini SM, Romani S, Mirtalebi H, Azimzadeh P, Damavand B, Naghoosi H, Khanyaghma M, Sanati A, Zali MR. Phylogenetic analysis of hepatitis C virus strains and risk factors associated with infection and viral subtypes among Iranian patients. J Med Virol 2014;86:1342-9. [PMID: 24838700 DOI: 10.1002/jmv.23947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
70 El Ray A, Asselah T, Moucari R, El Ghannam M, Taha AA, Saber MA, Akl M, Atta R, Shemis M, Radwan AS, Ghali A, Paradis V, Marcellin P. Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C. Eur J Gastroenterol Hepatol 2013;25:421-7. [PMID: 23470266 DOI: 10.1097/MEG.0b013e32835c9f69] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
71 El-araby HA, Behairy BE, El-guindi MA, Adawy NM, Allam AA, Sira AM, Khedr MA, Elhenawy IA, Sobhy GA, Basiouny HEDM, Salem ME, Abdel-aziz SA, Fouad OA, Ayoub BA. Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9–12 years) and adolescents. Hepatol Int 2019;13:706-14. [DOI: 10.1007/s12072-019-09985-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
72 Naghi SE, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol 2014; 20(16): 4681-4691 [PMID: 24782620 DOI: 10.3748/wjg.v20.i16.4681] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
73 Dabbous HM, Elmeteini MS, Sakr MA, Montasser IF, Bahaa M, Abdelaal A, Fathy M, Refaie R, Seyam M, Abdelmonem A, Mukhtar A, Hegazy N, Almoneiri M. Optimizing outcome of recurrent hepatitis C virus genotype 4 after living donor liver transplantation: moving forward by looking back. Transplant Proc 2014;46:822-7. [PMID: 24767357 DOI: 10.1016/j.transproceed.2013.11.152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Romana Ponziani F, Milani A, Gasbarrini A, Zaccaria R, Viganò R, Francesca Donato M, Cristina Morelli M, Miglioresi L, Pasulo L, Rendina M, Di Paolo D, Marino M, Toniutto P, Fagiuoli S, Pompili M. Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study. Annals of Hepatology 2012;11:338-42. [DOI: 10.1016/s1665-2681(19)30929-9] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
75 Breitinger U, Farag NS, Ali NKM, Breitinger HA. Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors. Biophys J 2016;110:2419-29. [PMID: 27276260 DOI: 10.1016/j.bpj.2016.04.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
76 Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823 [PMID: 26478672 DOI: 10.3748/wjg.v21.i38.10811] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
77 Safi SZ, Waheed Y, Sadat J, Solat-Ul-Islam, Salahuddin S, Saeed U, Ashraf M. Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. Asian Pac J Trop Biomed 2012;2:532-6. [PMID: 23569965 DOI: 10.1016/S2221-1691(12)60091-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
78 El Hadad S, Al-Hamdan H, Linjawi S. Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia. PLoS One 2017;12:e0178225. [PMID: 28552946 DOI: 10.1371/journal.pone.0178225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
79 Ibrahim DM, Shaaban ESE, Fouad TA. Circulating Resistin Is Associated with Plasma Glucagon-Like Peptide-1 in Cirrhotic Patients with Hepatitis C Virus Genotype-4 Infection. Endocr Res 2020;45:17-23. [PMID: 31177870 DOI: 10.1080/07435800.2019.1627551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Calado RA, Rocha MR, Parreira R, Piedade J, Venenno T, Esteves A. Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. J Med Virol. 2011;83:608-615. [PMID: 21328374 DOI: 10.1002/jmv.21955] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
81 Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, Zoulim F, Grange J, Shukla U, Lenz O, Ouwerkerk-mahadevan S, Fevery B, Peeters M, Beumont M, Jessner W. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. Journal of Hepatology 2015;62:1047-55. [DOI: 10.1016/j.jhep.2014.12.031] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
82 Jun BG, Park EJ, Lee WC, Jang JY, Jeong SW, Kim YD, Cheon GJ, Cho YS, Lee SH, Kim HS, Lee YN, Kim SG, Kim YS, Kim BS. Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C. Korean J Intern Med 2019;34:989-97. [PMID: 29529840 DOI: 10.3904/kjim.2017.322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, McPhee F. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. J Infect Dis 2016;213:206-15. [PMID: 26170396 DOI: 10.1093/infdis/jiv379] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
84 Degré D, Sersté T, Lasser L, Delwaide J, Starkel P, Laleman W, Langlet P, Reynaert H, Bourgeois S, Vanwolleghem T, Negrin Dastis S, Gustot T, Geerts A, Van Steenkiste C, de Galocsy C, Lepida A, Orlent H, Moreno C. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. PLoS One 2017;12:e0170933. [PMID: 28125694 DOI: 10.1371/journal.pone.0170933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
85 Hanafy AS, Farag AA, Hassanin HM, Hassaneen AM. Recombinant HBV vaccine enhances the rate of sustained virological response when early initiated after anti-HCV combination therapy. J Med Virol 2016;88:86-93. [PMID: 26147509 DOI: 10.1002/jmv.24317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Fathi HM, Abdel Wahed WY, Gomaa AA, Hassan EA, Eid HM, Reheem FA, Senara SH. A prospective study in hepatitis C virus treatment-naïve patients showing rheumatologic extra-hepatic manifestations of hepatitis C with associated risk factors: efficacy and safety using sofosbuvir-based direct antiviral therapy. Egypt Rheumatol Rehabil 2020;47. [DOI: 10.1186/s43166-020-00023-4] [Reference Citation Analysis]
87 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023] [Cited by in Crossref: 847] [Cited by in F6Publishing: 805] [Article Influence: 77.0] [Reference Citation Analysis]
88 Shemis MA, El-abd DM, Ramadan DI, El-sayed MI, Guirgis BS, Saber MA, El-said Azzazy HM. Evaluation of Multiplex Nested Polymerase Chain Reaction for Routine Hepatitis C Virus Genotyping in Egyptian Patients. Hepat Mon 2012;12:265-70. [DOI: 10.5812/hepatmon.6012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
89 Hammad LN, Abdelraouf SM, Hassanein FS, Mohamed WA, Schaalan MF. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis? J Immunotoxicol. 2013;10:380-386. [PMID: 23350952 DOI: 10.3109/1547691x.2012.758198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
90 Cho EJ, Jeong SH, Han BH, Lee SU, Yun BC, Park ET. Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience. Clin Mol Hepatol. 2012;18:219-224. [PMID: 22893873 DOI: 10.3350/cmh.2012.18.2.219] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
91 Ahmed HR, Waly NGFM, Abd El-Baky RM, Yahia R, Hetta HF, Elsayed AM, Ibrahem RA. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C. PLoS One 2021;16:e0249770. [PMID: 33857212 DOI: 10.1371/journal.pone.0249770] [Reference Citation Analysis]
92 Badawi MM, Mohammed AA, Mohammed MS, Saeed MM, Ali EY, Khalil A. A Diagnostic Laboratory-Based Study on Frequency and Distribution of Viral Hepatitis B and C Among Sudanese. Open Virol J. 2017;11:98-107. [PMID: 29399232 DOI: 10.2174/1874357901711010098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Minosse C, Salichos L, Taibi C, Luzzitelli I, Nardozi D, Capobianchi MR, D'Offizi G, McPhee F, Garbuglia AR. Phylogenetic and Phylodynamic Analyses of HCV Strains Circulating among Patients Using Injectable Drugs in Central Italy. Microorganisms 2021;9:1432. [PMID: 34361868 DOI: 10.3390/microorganisms9071432] [Reference Citation Analysis]
94 Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013;20:35-40. [PMID: 23723729 DOI: 10.4103/2230-8229.108182] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
95 Ngui SL, Brant L, Markov PV, Tung JP, Pybus OG, Teo CG, Ramsay ME. Hepatitis C virus genotype 4 in England: diversity and demographic associations. J Med Virol 2015;87:417-23. [PMID: 25185790 DOI: 10.1002/jmv.24069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
96 Helal TESA, Ehsan NA, Radwan NA, Abdelsameea E. Relationship between hepatic progenitor cells and stellate cells in chronic hepatitis C genotype 4. APMIS 2018;126:14-20. [PMID: 29155473 DOI: 10.1111/apm.12787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
97 Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136:856-62. [PMID: 19135998 DOI: 10.1053/j.gastro.2008.11.037] [Cited by in Crossref: 114] [Cited by in F6Publishing: 99] [Article Influence: 8.1] [Reference Citation Analysis]
98 Rimmert B, Sabet S, Ackad E, Yousef MS. A 3D structural model and dynamics of hepatitis C virus NS3/4A protease (genotype 4a, strain ED43) suggest conformational instability of the catalytic triad: implications in catalysis and drug resistivity. J Biomol Struct Dyn 2014;32:950-8. [PMID: 23768174 DOI: 10.1080/07391102.2013.800001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
99 Zayed N, Gamal Eldeen H, Elmakhzangy H, Seif M, El-Akel W, Awad T, Esmat G, Mabrouk M. Therapeutic outcome of 6198 interferon-naïve Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era. J Viral Hepat 2016;23:506-11. [PMID: 26936687 DOI: 10.1111/jvh.12514] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Gomaa WM, Ibrahim MA, Shatat ME. Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients. Saudi J Gastroenterol. 2014;20:59-65. [PMID: 24496160 DOI: 10.4103/1319-3767.126324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
101 El Missiri AM, Rayan MM, Awad MM, El Desoky AI. Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring. Egypt Heart J 2020;72:37. [PMID: 32613565 DOI: 10.1186/s43044-020-00070-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Kamal S, Abdelhakam S, Ghoraba D, Mohsen MA, Salam AA, Hassan H, Nabeigh L. The Course of Hepatitis C Infection and Response to Anti-viral Therapy in Patients with Thalassemia major and Hepatitis C Infection: A Longitudinal, Prospective Study. Mediterr J Hematol Infect Dis 2019;11:e2019060. [PMID: 31700585 DOI: 10.4084/MJHID.2019.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
103 Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges: HCV genotype 4 therapy. Liver International 2011;31:45-52. [DOI: 10.1111/j.1478-3231.2010.02385.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
104 Massariol MJ, Zhao S, Marquis M, Thibeault D, White PW. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. Biochem Biophys Res Commun 2010;391:692-7. [PMID: 19944069 DOI: 10.1016/j.bbrc.2009.11.122] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
105 Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008;28:574-80. [PMID: 18616643 DOI: 10.1111/j.1365-2036.2008.03781.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 4.5] [Reference Citation Analysis]
106 Tabll A, El Shenawy R, Elsharkawy H, Mohamed FZ. Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patients. Hum Antibodies 2019;27:265-73. [PMID: 31127759 DOI: 10.3233/HAB-190381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Al-Hamoudi WK. Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol 2016;22:173-82. [PMID: 27184634 DOI: 10.4103/1319-3767.182453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
108 Mogahed EA, Sayed AA, Khalifa SE, El-Hennawy A, El-Raziky MS. Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years. Eur J Pediatr 2020;179:719-26. [PMID: 31897838 DOI: 10.1007/s00431-019-03551-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
109 Cuadros DF, Miller FD, Nagelkerke N, Abu-Raddad LJ. Association between HCV infection and diabetes type 2 in Egypt: is it time to split up? Ann Epidemiol. 2015;25:918-923. [PMID: 26499381 DOI: 10.1016/j.annepidem.2015.09.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
110 Gabr SA, Alghadir AH, Allam AA, Ajarem J, Al-Basher G, Abdel-Maksoud MA, Ghfar AA, Aboud A. Correlation between vitamin D levels and apoptosis in geriatric patients infected with hepatitis C virus genotype 4. Clin Interv Aging 2016;11:523-33. [PMID: 27217734 DOI: 10.2147/CIA.S104599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
111 Elbaz T, Elserafy M, Elakel W, Mohey MA, Abdo M, Hassany M, Mehrez M, Abouelkhair M, Yosry A, Omar A, Waked I, Elsayed MH, Mahran Z, Elshazly Y, Elgarem N, Gaballa A, Doss W, Esmat G. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. J Interferon Cytokine Res 2017;37:348-53. [PMID: 28777714 DOI: 10.1089/jir.2016.0131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Othman AA, Eissa AA, Markous RD, Ahmed BD, Al-Allawi NA. Hepatitis C virus genotypes among multiply transfused hemoglobinopathy patients from Northern Iraq. Asian J Transfus Sci 2014;8:32-4. [PMID: 24678171 DOI: 10.4103/0973-6247.126687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
113 Alfaleh FZ, Alswat K, Helmy A, Al-hamoudi W, El-sharkawy M, Omar M, Shalaby A, Bedewi MA, Hadad Q, Ali SM, Alfaleh A, Abdo AA. The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. Liver Int 2013;33:871-83. [PMID: 23490034 DOI: 10.1111/liv.12127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
114 El-Shabrawi MHF, Kamal NM, El-Khayat HR, Kamal EM, AbdElgawad MMAH, Yakoot M. A pilot single arm observational study of sofosbuvir/Ledipasvir (200 + 45 mg) in 6- to 12- year old children. Aliment Pharmacol Ther. 2018;47:1699-1704. [PMID: 29696674 DOI: 10.1111/apt.14677] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
115 Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, Pisaturo M. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty 2019;8:17. [PMID: 30871599 DOI: 10.1186/s40249-019-0528-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
116 Rouabhia S, Sadelaoud M, Chaabna-Mokrane K, Toumi W, Abenavoli L. Hepatitis C virus genotypes in north eastern Algeria: A retrospective study. World J Hepatol 2013; 5(7): 393-397 [PMID: 23898373 DOI: 10.4254/wjh.v5.i7.393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
117 Abdelaziz DH, Elhosseiny NM, Khaleel SA, Sabry NA, Attia AS, El-Sayed MH. Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer 2016;63:1539-45. [PMID: 27163515 DOI: 10.1002/pbc.26045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
118 El-Shabrawi MHF, Kamal NM, Mogahed EA, Elhusseini MA, Aljabri MF. Perinatal transmission of hepatitis C virus: an update. Arch Med Sci 2020;16:1360-9. [PMID: 33224335 DOI: 10.5114/aoms.2019.83644] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
119 Gewaid H, Mesalam AA, Ibrahim AA, Abdel Shafy DN, Abdel Shafy RN, Emara N, Hamdy SM, Gewaid M, Bahgat MM. Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate. J Med Virol 2018;90:545-58. [PMID: 29064582 DOI: 10.1002/jmv.24977] [Reference Citation Analysis]
120 Khan A, Al Balwi M, AlAyyar L, AlAbdulkareem I, Albekairy A, Aljumah A. Tracing the epidemic history of hepatitis C virus genotypes in Saudi Arabia. Infect Genet Evol 2017;52:82-8. [PMID: 28458032 DOI: 10.1016/j.meegid.2017.04.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
121 Al-Tawil MM, Shoeeb AS, Abbas A, El-Tawil A, El-Sayed MH. Lipid profile and hepatic steatosis in hepatitis C infected egyptian survivors of childhood cancer. Pediatr Hematol Oncol 2015;32:70-7. [PMID: 24050726 DOI: 10.3109/08880018.2013.825355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
122 Jamalidoust M, Namayandeh M, Asaei S, Aliabadi N, Ziyaeyan M. Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol 2014; 20(19): 5897-5902 [PMID: 24914351 DOI: 10.3748/wjg.v20.i19.5897] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
123 Demetriou VL, van de Vijver DA, Kostrikis LG. Molecular epidemiology of hepatitis C infection in Cyprus: evidence of polyphyletic infection. J Med Virol. 2009;81:238-248. [PMID: 19107977 DOI: 10.1002/jmv.21370] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
124 Rose R, Markov PV, Lam TT, Pybus OG. Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation. Infect Genet Evol. 2013;20:418-421. [PMID: 24140473 DOI: 10.1016/j.meegid.2013.09.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
125 Al-Qahtani AA, Baele G, Khalaf N, Suchard MA, Al-Anazi MR, Abdo AA, Sanai FM, Al-Ashgar HI, Khan MQ, Al-Ahdal MN, Lemey P, Vrancken B. The epidemic dynamics of hepatitis C virus subtypes 4a and 4d in Saudi Arabia. Sci Rep 2017;7:44947. [PMID: 28322313 DOI: 10.1038/srep44947] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
126 Saleh NA, Elshemey WM. Structure-based drug design of novel peptidomimetic cellulose derivatives as HCV-NS3 protease inhibitors. Life Sci 2017;187:58-63. [PMID: 28842311 DOI: 10.1016/j.lfs.2017.08.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
127 Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010;105:1970-7. [PMID: 20234345 DOI: 10.1038/ajg.2010.110] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
128 Bendas ER, Rezk MR, Badr KA. Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers. Clin Drug Investig 2018;38:439-48. [PMID: 29417463 DOI: 10.1007/s40261-018-0622-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
129 Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Rev Gastroenterol Hepatol 2008;5:610-22. [DOI: 10.1038/ncpgasthep1274] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 4.7] [Reference Citation Analysis]
130 de Bruijne J, Schinkel J, Prins M, Koekkoek SM, Aronson SJ, van Ballegooijen MW, Reesink HW, Molenkamp R, van de Laar TJ. Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol. 2009;47:3832-3838. [PMID: 19794040 DOI: 10.1128/jcm.01146-09] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
131 Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother 2015;59:6807-15. [PMID: 26282418 DOI: 10.1128/AAC.01229-15] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
132 Khairy M, Fouad R, Mabrouk M, El-Akel W, Awad AB, Salama R, Elnegouly M, Shaker O. The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis. Hepat Mon 2013;13:e10509. [PMID: 24065997 DOI: 10.5812/hepatmon.10509] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
133 Rossignol JF, Elfert A, Keeffe EB. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. J Clin Gastroenterol 2010;44:504-9. [PMID: 20048684 DOI: 10.1097/MCG.0b013e3181bf9b15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
134 Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, Ghys A, Luo D, Picchio GR, Beumont M. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis 2013;208:1000-7. [PMID: 23801602 DOI: 10.1093/infdis/jit274] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
135 Zayed N, Awad AB, El-Akel W, Doss W, Awad T, Radwan A, Mabrouk M. The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2013;37:254-61. [PMID: 23141214 DOI: 10.1016/j.clinre.2012.09.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
136 González-casas R, Trapero-marugán M, Moreno-otero R. Hepatitis crónica por virus de la hepatitis C genotipo 4. Medicina Clínica 2011;137:31-5. [DOI: 10.1016/j.medcli.2010.03.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 El-Tahan RR, Ghoneim AM, Zaghloul H. 5' UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt. J Adv Res 2018;10:39-47. [PMID: 30046475 DOI: 10.1016/j.jare.2018.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
138 Biomy R, Abdelshafy M, Abdelmonem A, Abu-Elenin H, Ghaly G. Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System. Clin Med Insights Cardiol 2017;11:1179546817713204. [PMID: 28804248 DOI: 10.1177/1179546817713204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
139 Ramia S, Melhem NM, Kreidieh K. Hepatitis C virus infection in the Middle East and North Africa “MENA” region: injecting drug users (IDUs) is an under-investigated population. Infection. 2012;40:1-10. [PMID: 22237470 DOI: 10.1007/s15010-011-0236-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
140 Yang SS, Kao JH. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatol Int 2016;10:258-66. [PMID: 26542068 DOI: 10.1007/s12072-015-9668-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
141 El-Fishawy H, Saadi G, Hassaballa M, Hussein M, Doss W, Ragab G, Barsoum R. Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective. J Adv Res 2016;7:391-402. [PMID: 27222744 DOI: 10.1016/j.jare.2016.02.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
142 Herbst DA Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs. 2013;22:527-536. [PMID: 23448131 DOI: 10.1517/13543784.2013.775246] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
143 Li C, Lu L, Wu X, Wang C, Bennett P, Lu T, Murphy D. Complete genomic sequences for hepatitis C virus subtypes 4b, 4c, 4d, 4g, 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r and 4t. J Gen Virol 2009;90:1820-6. [PMID: 19357224 DOI: 10.1099/vir.0.010330-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
144 Hamdy HS, Abdelkader NA, Mansour A, Allam EH, El-Wakiel HM, Elshenawy D. B cell non-Hodgkin's lymphoma in chronic hepatitis C virus patients: An interesting relationship. Indian J Gastroenterol 2015;34:127-34. [PMID: 25917521 DOI: 10.1007/s12664-015-0549-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Papastergiou V, Dimitroulopoulos D, Skorda L, Lisgos P, Ketikoglou I, Kostas N, Karatapanis S. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol. 2012;84:1217-1223. [PMID: 22711349 DOI: 10.1002/jmv.23324] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
146 El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013; 19(44): 7880-7888 [PMID: 24307782 DOI: 10.3748/wjg.v19.i44.7880] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 71] [Article Influence: 9.8] [Reference Citation Analysis]
147 Kirdar S, Aydin N, Tiryaki Y, Ertugrul B, Coskun A, Bilgen M. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors. APMIS 2018;126:109-13. [PMID: 29271117 DOI: 10.1111/apm.12790] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
148 Shawkat H, Yakoot M, Shawkat T, Helmy S. Efficacy and safety of a herbal mixture (Viron® tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study. Drug Des Devel Ther 2015;9:799-804. [PMID: 25709404 DOI: 10.2147/DDDT.S77168] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Pawłowska M, Janczewska E, Berak H, Janocha-Litwin J, Klapaczyński J, Tomasiewicz K, Piekarska A, Krygier R, Citko J, Tronina O, Dobrowolska K, Flisiak R. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. J Clin Med 2022;11:389. [PMID: 35054088 DOI: 10.3390/jcm11020389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Tabernilla A, Rego-Pérez I, Grandal M, Pernas B, Pértega S, Delgado M, Mariño A, Álvarez H, Mena A, Rodríguez-Osorio I, Pedreira JD, Blanco FJ, Poveda E. Brief Report: European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest Spain. J Acquir Immune Defic Syndr 2016;73:149-53. [PMID: 27258234 DOI: 10.1097/QAI.0000000000001097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
151 Chevaliez S, Bouvier-Alias M, Rodriguez C, Soulier A, Poveda JD, Pawlotsky JM. The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA. J Clin Microbiol. 2013;51:1078-1082. [PMID: 23325825 DOI: 10.1128/jcm.02004-12] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
152 Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013;20:35-40. [PMID: 23723729 DOI: 10.4103/2230-8229.108182] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
153 Derbala M, Rizk NM, Al-Kaabi S, John A, Sharma M, El-dweik N, Yakoob R, Pasic F, Almohanadi M, Alejji K. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Virology. 2013;444:292-300. [PMID: 23866096 DOI: 10.1016/j.virol.2013.06.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
154 Ciccozzi M, Zehender G, Polat C, Lai A, Kayman T, Sorrentino C, Ebranati E, Cella E, Lo Presti A, Abacioglu H. Phylogenetic analysis of HCV-4d in Turkey: the curious case of Kayseri province. J Med Virol. 2014;86:454-460. [PMID: 24132509 DOI: 10.1002/jmv.23787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
155 Esmat G, Elbaz T, El Raziky M, Gomaa A, Abouelkhair M, Gamal El Deen H, Sabry A, Ashour M, Allam N, Abdel-hamid M, Nada O, Helmy S, Abdel-maguid H, Colonno R, Brown N, Ruby E, Vig P, Waked I. Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. Journal of Hepatology 2018;68:53-62. [DOI: 10.1016/j.jhep.2017.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
156 Rady NH, Darwish RK, Mogahed EA, Mandour IA, Abo Youssef H, Sharaf SAA, El-karaksy HM. Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4. Cytokine 2015;75:349-55. [DOI: 10.1016/j.cyto.2015.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
157 Wahid A, Hamzawy MA, Khalifa MMA, Gad GFM, Bekhit A, Abdelwahab SF. RNA protein kinase SNP at −226 C<T is a biomarker for the clearance of HCV among Egyptian patients. Immunological Investigations 2019;48:211-21. [DOI: 10.1080/08820139.2018.1493496] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
158 Shehat MG, Bahey-El-Din M, Kassem MA, Farghaly FA, Abdul-Rahman MH, Fanaki NH. Recombinant expression of the alternate reading frame protein (ARFP) of hepatitis C virus genotype 4a (HCV-4a) and detection of ARFP and anti-ARFP antibodies in HCV-infected patients. Arch Virol 2015;160:1939-52. [PMID: 26036563 DOI: 10.1007/s00705-015-2465-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
159 Yakoot M, Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC Gastroenterol. 2012;12:32. [PMID: 22497849 DOI: 10.1186/1471-230x-12-32] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
160 O'Leary JG, Davis GL. Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol 2010;3:43-53. [PMID: 21180589 DOI: 10.1177/1756283X09353353] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
161 Shaker O, Rashad A, Abd El Aziz G, El Raziky M. Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study. Cell Biochem Biophys 2015;71:307-14. [PMID: 25115611 DOI: 10.1007/s12013-014-0199-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
162 Dietz J, Kalinina OV, Vermehren J, Peiffer K, Matschenz K, Buggisch P, Niederau C, Schattenberg JM, Müllhaupt B, Yerly S, Ringelhan M, Schmid RM, Antoni C, Müller T, Schulze zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg CP, Zeuzem S, Welsch C, Sarrazin C; European HCV Resistance Study Group. Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. J Viral Hepat 2020;27:974-86. [DOI: 10.1111/jvh.13322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
163 Liberto MC, Marascio N, Zicca E, Matera G. Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region. BMC Infect Dis. 2012;12 Suppl 2:S4. [PMID: 23173638 DOI: 10.1186/1471-2334-12-s2-s4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
164 Demetriou VL, Kostrikis LG. Near-full genome characterization of unclassified hepatitis C virus strains relating to genotypes 1 and 4. J Med Virol 2011;83:2119-27. [PMID: 22012719 DOI: 10.1002/jmv.22237] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
165 Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS One 2018;13:e0205186. [PMID: 30286205 DOI: 10.1371/journal.pone.0205186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
166 Shemis MA, El-Abd DM, Ramadan DI, El-Sayed MI, Guirgis BS, Saber MA, Azzazy HM. Evaluation of multiplex nested polymerase chain reaction for routine hepatitis C virus genotyping in egyptian patients. Hepat Mon 2012;12:265-70. [PMID: 22690234 DOI: 10.5812/hepatmon.830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
167 Eltayeb AA, Abdou MAA, Abdel-aal AM, Othman MH. Vitamin D status and viral response to therapy in hepatitis C infected children. World J Gastroenterol 2015; 21(4): 1284-1291 [PMID: 25632203 DOI: 10.3748/wjg.v21.i4.1284] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
168 Xia X, Zhao W, Tee KK, Feng Y, Takebe Y, Li Q, Pybus OG, Lu L. Complete genome sequencing and phylogenetic analysis of HCV isolates from China reveals a new subtype, designated 6u. J Med Virol. 2008;80:1740-1746. [PMID: 18712831 DOI: 10.1002/jmv.21287] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
169 Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M, López Nuñez C, Serra Matamala I, Queralt Molés X, Aldeguer Manté X. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol Hepatol 2018;41:2-11. [PMID: 29150360 DOI: 10.1016/j.gastrohep.2017.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
170 Youssef SS, Fahmy AM, Omran MH, Mohamed AS, El Desouki MA, El-Awady MK. In vitro inhibition of hepatitis C virus by antisense oligonucleotides in PBMC compared to hepatoma cells. Biomed Res Int 2014;2014:196712. [PMID: 24991538 DOI: 10.1155/2014/196712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
171 Hadinedoushan H, Salmanroghani H, Amirbaigy MK, Akhondi-Meybodi M. Hepatitis C virus genotypes and association with viral load in yazd, central province of iran. Hepat Mon 2014;14:e11705. [PMID: 24693314 DOI: 10.5812/hepatmon.11705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
172 Urquijo JJ, Diago M, Boadas J, Planas R, Solá R, del Olmo JA, Crespo J, Erdozaín JC, Antón MD, Arocena C, Suarez D, Giné J, Barrera JM, Gracia-samaniego J, Perez R, Dalmau B, Montoro M. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Annals of Hepatology 2013;12:30-5. [DOI: 10.1016/s1665-2681(19)31382-1] [Cited by in Crossref: 8] [Article Influence: 0.9] [Reference Citation Analysis]
173 Reddy KR, Lin F, Zoulim F. Response-guided and -unguided treatment of chronic hepatitis C. Liver Int. 2012;32 Suppl 1:64-73. [PMID: 22212575 DOI: 10.1111/j.1478-3231.2011.02713.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
174 Tierney AR, Huepfel W, Shaukat AP, Lake JR, Boldt M, Wang Q, Hassan MA. Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community. J Immigr Minor Health 2019;21:549-54. [PMID: 29802526 DOI: 10.1007/s10903-018-0758-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 El Shazly Y, Hemida K, Rafik M, Al Swaff R, Ali-Eldin ZA, GadAllah S. Detection of occult hepatitis C virus among healthy spouses of patients with HCV infection. J Med Virol. 2015;87:424-427. [PMID: 25185940 DOI: 10.1002/jmv.24074] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
176 Bonnard P, Elsharkawy A, Zalata K, Delarocque-Astagneau E, Biard L, Le Fouler L, Hassan AB, Abdel-Hamid M, El-Daly M, Gamal ME. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt. J Viral Hepat. 2015;22:245-253. [PMID: 25073725 DOI: 10.1111/jvh.12285] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
177 Schaalan MF, Mohamed WA, Amin HH. Vitamin D deficiency: Correlation to interleukin-17, interleukin-23 and PIIINP in hepatitis C virus genotype 4. World J Gastroenterol 2012; 18(28): 3738-3744 [PMID: 22851868 DOI: 10.3748/wjg.v18.i28.3738] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
178 Abdelaty LN, Elnaggar AA, Said AA, Hussein RRS. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. Curr Drug Saf 2020;15:53-60. [PMID: 31573893 DOI: 10.2174/1574886314666191001151314] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
179 Asante-Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, Qiu P, Howe A, Lahser FC. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons. Antimicrob Agents Chemother 2017;61:e00363-17. [PMID: 28416549 DOI: 10.1128/AAC.00363-17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
180 Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010;30:447-54. [PMID: 19919569 DOI: 10.1111/j.1478-3231.2009.02171.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 5.5] [Reference Citation Analysis]
181 Kamal SM. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int. 2009;29 Suppl 1:39-48. [PMID: 19207965 DOI: 10.1111/j.1478-3231.2008.01930.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
182 Gouda HM, El-saadany ZA, Foad NB, Salama RM. Interleukin 28B Polymorphisms and Therapy Response in Egyptian Hepatitis C Genotype-4 Patients. DNA and Cell Biology 2014;33:642-6. [DOI: 10.1089/dna.2014.2489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
183 European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32 Suppl 1:2-8. [PMID: 22212565 DOI: 10.1111/j.1478-3231.2011.02703.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 6.1] [Reference Citation Analysis]
184 Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad YK. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. 2018;163:51-56. [PMID: 28983675 DOI: 10.1007/s00705-017-3573-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
185 Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342-355. [PMID: 20015149 DOI: 10.1111/j.1478-3231.2009.02188.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 109] [Article Influence: 8.8] [Reference Citation Analysis]